NCT02988817 · MORE INFO

Limitations, agreements, and source contact

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors · Source last updated 2023-08-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 12 months but less than 18 months from the end of study (database lock). The sponsor cannot require changes to the communication and cannot extend the embargo.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

limitations And Caveats

description: No participants with castration-resistant prostate cancer were enrolled, hence no prostate-specific antigen (PSA) data were available and pre-specified outcome measure related to PSA data are not reported.

point Of Contact

Complete source fields

certain Agreement

other Details: The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 12 months but less than 18 months from the end of study (database lock). The sponsor cannot require changes to the communication and cannot extend the embargo.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

limitations And Caveats

description: No participants with castration-resistant prostate cancer were enrolled, hence no prostate-specific antigen (PSA) data were available and pre-specified outcome measure related to PSA data are not reported.

point Of Contact

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice